Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis-Reference-Cited by-同舟云学术

Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis

Published:2010-12 Issue:9756 Volume:376 Page:1916-1922
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Athyros Vasilios G,Tziomalos Konstantinos,Gossios Thomas D,Griva Theodora,Anagnostis Panagiotis,Kargiotis Konstantinos,Pagourelias Efstathios D,Theocharidou Eleni,Karagiannis Asterios,Mikhailidis Dimitri P

Publisher

Elsevier BV

Subject

General Medicine

Reference30 articles.

1. Impact of statin dosing intensity on transaminase and creatine kinase;Dale;Am J Med,2007

2. Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients;Newman;Am J Cardiol,2006

3. Evaluation and management of non-alcoholic steatohepatitis;Ramesh;J Hepatol,2005

4. American Gastroenterological Association medical position statement: nonalcoholic fatty liver disease;Gastroenterology,2002

5. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study;Athyros;Curr Med Res Opin,2006

Cited by 594 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD);Journal of Hepatology;2024-09

2. Mechanisms of Non-alcoholic Fatty Liver Disease and Beneficial Effects of Semaglutide: A Review;Cureus;2024-08-17

3. Prevalence, Associated Risk Factors, and Adverse Cardiovascular Outcomes of Statins Discontinuation: A Systematic Review;Pharmacoepidemiology and Drug Safety;2024-08

4. Objective Measures of Cardiometabolic Risk and Advanced Fibrosis Risk Progression in Primary Care Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease;Endocrine Practice;2024-08

5. Exploring Varied Treatment Strategies for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD);Life;2024-07-03